4Tissue, a Ghent, Belgium-based biotechnology company which specializes in regenerative medicine, raised additional €1.5M in funding.
The round consisted of €1M equity investments from strategic investors and grants.
The company intends to use the funds to support the further development of its bioresorbable hydrogel technology, which has the potential to improve breast reconstruction and other tissue regeneration applications.
Founded by Prof. Phillip Blondeel and Prof. Dr. Sandra Van Vlierberghe, and led by CEO Dr. Benoit Moreaux, 4Tissue is a biotech company improving regenerative medicine, utilizing advanced bio-interactive hydrogels to transition from cells to tissue engineering. It is a spin-off from Ghent University (UGent), Ghent University Hospital (UZGent), and the Vrije Universiteit Brussel (VUB).
The company develops natural and minimally invasive treatments for tissue reconstruction and regeneration, with applications in different medical fields.
Other founders include Dr. A Van Den Bulcke (COO), Dr. Lana Van Damme, MD (CSO), and Bernard Depypere, MD.
In addition to this financial milestone, 4Tissue added Dr. Katleen Verleysen, currently CEO of miDiagnostics, as the independent chair of the board.
FinSMEs
26/02/2025